Jr. Sarcoma/Melanoma Physician

Hackensack, NJ

Inpatient and outpatient

Full Time Jr. Melanoma Sarcoma Physician Opportunity

The John Theurer Cancer Center (JTCC), a part of Georgetown Lombardi Comprehensive Cancer Center, an NCI-designated cancer center, and New Jersey’s largest cancer program, is seeking an outstanding junior to mid-career Medical Oncologist/Hematologist specializing in Melanoma/Sarcoma. The successful candidate will join a growing group of 30 specialized Medical Oncologists and Hematologists in the JTCC, which is in Northern New Jersey.

This opportunity at Hackensack Meridian School of Medicine, John Theurer Cancer Center, features the best from both the academic and private practice environments. Our physicians are disease-focused specialists who actively participate in clinical and translational research, the education of students, residents, and fellows, all while practicing in a well-run, successful non-profit health system that offers competitive physician salaries. The Center for Discovery and Innovation, and its National Institute of Health-funded faculty work with the physicians at the JTCC to advance clinical, genomic, and translational research in cancer diagnosis and treatment. We have a robust clinical research program supporting industry sponsored, NCI, and investigator-initiated clinical trials. We are a primary site for the Alliance NCI cooperative group and the Multiple Myeloma Research Foundation. As part of a health care system that is evolving to meet the needs of the rapidly growing and diverse region in northern NJ and the metropolitan New York City area, the John Theurer Cancer Center strives to become one of the premiere centers for cancer care on the East Coast and across the nation over the next decade.

This position offers a competitive salary and a comprehensive benefits package which includes medical, dental, life insurance and 401K.

Interested candidates should send their CV and cover letter to Nicole Panzarella, via e-mail to: Nicole.Panzarella@hmhn.org

Posted April 28, 2021